RAPT Q2 2024 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

$959M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$28M

EPS (Diluted)

$-5.69

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$127M

Total Liabilities

$18M

Stockholders' Equity

$109M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$29M	-$28M	-3.4%
Net Income	-$28M	-$25M	-9.4%